Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug 26;31(9):2740-2742.
doi: 10.1016/j.numecd.2021.06.008. Epub 2021 Jun 29.

Authors' response: Meta-analysis of statin and outcomes of coronavirus disease 2019 (COVID-19)

Affiliations
Comment

Authors' response: Meta-analysis of statin and outcomes of coronavirus disease 2019 (COVID-19)

Timotius Ivan Hariyanto et al. Nutr Metab Cardiovasc Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare no conflict of interest.

Comment on

References

    1. Tandaju J.R., Li W., Barati-Boldaji R., Raeisi-Dehkordi H. Meta-analysis of statin and outcomes of coronavirus disease 2019 (COVID-19): reconsideration is needed. Nutr Metabol Cardiovasc Dis. 2021;31:2737–2739. - PMC - PubMed
    1. Hariyanto T.I., Kurniawan A. Statin and outcomes of coronavirus disease 2019 (COVID-19): a systematic review, meta-analysis, and meta-regression. Nutr Metabol Cardiovasc Dis. 2021;31:1662–1670. - PMC - PubMed
    1. Hariyanto T.I., Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1613–1615. doi: 10.1016/j.dsx.2020.08.023. - DOI - PMC - PubMed
    1. Bull-Otterson L., Gray E.B., Budnitz D.S., Strosnider H.M., Schieber L.Z., Courtney J. Hydroxychloroquine and chloroquine prescribing patterns by provider specialty following initial reports of potential benefit for COVID-19 treatment - United States, january-june 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 4;69(35):1210–1215. doi: 10.15585/mmwr.mm6935a4. - DOI - PMC - PubMed
    1. Moher D., Liberati A., Tetzlaff J., Altman D.G., PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7) doi: 10.1371/journal.pmed.1000097. - DOI - PMC - PubMed

Substances